Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Austar Lifesciences's share price for the quarter that ended in Dec. 2025 was $0.07. Austar Lifesciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 512.6 Mil. Therefore, Austar Lifesciences's market cap for the quarter that ended in Dec. 2025 was $35.9 Mil.
Austar Lifesciences's quarterly market cap
increased
from Dec. 2024 ($2.6 Mil) to Jun. 2025 ($35.9 Mil) but then
stayed the same
from Jun. 2025 ($35.9 Mil) to Dec. 2025 ($35.9 Mil).
Austar Lifesciences's annual market cap
increased
from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($2.6 Mil) and
increased
from Dec. 2024 ($2.6 Mil) to Dec. 2025 ($35.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Austar Lifesciences's Enterprise Value for Today is $30.6 Mil.
Austar Lifesciences (OTCPK:AULSF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Austar Lifesciences Market Cap Related Terms
Austar Lifesciences Market Cap Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Austar Lifesciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a Market Cap of $13.3 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Austar Lifesciences and its competitors. According to the industry distribution chart, Austar Lifesciences ranks #548 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 63.2%.
Is Austar Lifesciences' Market Cap too high?
Austar Lifesciences' current Market Cap is $13.3 Mil. The Medical Devices & Instruments industry median Market Cap is 117.03. Austar Lifesciences' value of $13.3 Mil is 88.6% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #548 out of 867 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #548 out of 867 companies for Market Cap. This places Austar Lifesciences in the lower half of its industry. The industry median Market Cap is 117.03. Austar Lifesciences' value of $13.3 Mil is 88.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 117.03, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current Market Cap of $13.3 Mil is 88.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 117.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current Market Cap is $13.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current Market Cap of $13.3 Mil. The stock's GF Value™ is $0.10, compared to a current price of $0.02 — trading 80% below its estimated fair value. The current Market Cap is $13.3 Mil and 88.6% below the Medical Devices & Instruments industry median of 117.03. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current Market Cap is $13.3 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 80% below its estimated GF Value™ of $0.10.
Key valuation signals for AULSF:
Market Cap: $13.3 Mil
GF Value™: $0.10 vs. price of $0.02 (80% below fair value)
Industry Position: 88.6% below the Medical Devices & Instruments median (#548 of 867)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
